About Us
Vivesto is a Swedish drug development company that aims to offer new treatment options for hard-to-treat cancers where there are major medical needs and significant market potential.
The project portfolio consists of Cantrixil, which is being developed for blood cancer, and the veterinary oncology program Paccal Vet (paclitaxel micellar), which is being evaluated in a pilot clinical trial in dogs with splenic hemangiosarcoma following splenectomy and in a dose-finding study in cats with solid tumors.
Vivesto’s shares are traded on Nasdaq Stockholm (ticker: VIVE).
-
Regulatory May 7, 2026Report from Annual General Meeting in Vivesto AB
-
Regulatory April 1, 2026Notice of Annual General Meeting in Vivesto AB
-
Regulatory April 1, 2026The Board of Directors of Vivesto proposes a reverse share split and reduction of the share capital
Vivesto published its interim report for Q1 2026 on May 7, 2026, at 08.00 am CEST.